Case: Tricida, Inc.
Venue: NDCA
Class Period: 9/4/2019 - 10/28/2020
Lead Plaintiff Deadline: 3/8/2021
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW YORK, NY – January 29, 2021 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA).  A complaint has been filed on behalf of investors who purchased Tricida securities between September 4, 2019 and October 28, 2020 (the “Class Period”).

On July 15, 2020 after the market closed, Tricida announced that it had received a notification from the FDA that, as part of the FDA’s review of Tricida’s New Drug Application (NDA) for its drug candidate, veverimer, “the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.”  On this news, Tricida’s stock price fell $10.56 per share, more than 40%, to close at $15.64 per share on July 16, 2020.

Then on October 29, 2020, Tricida announced an update on its End-of-Review Type A meeting with the FDA concerning the veverimer NDA, stating that the “FDA is unlikely to rely solely on serum bicarbonate data for determination of efficacy.” On this news, Tricida’s stock price fell another $3.90 per share, over 47%, to close at $4.37 per share on October 29, 2020.

If you are a member of the proposed Class, you may move the court no later than March 8, 2021 to serve as a lead plaintiff for the purported class.  You need not seek to become a lead plaintiff in order to share in any possible recovery.  If you would like to discuss the complaint or our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling (646) 315-9003.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, your rights, or your interests, please contact: 

Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(646) 315-9003
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it